References

  1. Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf. 2011; 10(2):p159-69. PubMed | Google Scholar

  2. Palaniappan M et al. Anticancer drug induced palmar plantar erythrodysesthesia. J Clin Diagn Res. 2014; 8(10):pHc01-3. PubMed | Google Scholar

  3. Webster-Gandy JD, How C and Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007; 11(3): p 238-46. PubMed | Google Scholar

  4. Scheithauer W and Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park). 2004 Aug;18(9):1161-8, 1173. PubMed | Google Scholar

  5. Lin E, Morris JS and Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park). 2002;16(12 Suppl No 14): p 31-7. PubMed | Google Scholar

  6. Zhang RX et al. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol. 2011;137(6):p953-7. PubMed | Google Scholar

  7. Caronia D et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res. 2011; 17(7):p2006-13. PubMed | Google Scholar

  8. Shahrokni A, Rajebi MR and Saif MW. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: a challenge or a dilemma? Clin Colorectal Cancer. 2009; 8(4):p231-4. PubMed | Google Scholar

  9. Saif MW and Sandoval A. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?. Cutan Ocul Toxicol. 2008; 27(4): p 311-5. PubMed | Google Scholar

  10. Nagore E, Insa A and Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):p225-34. PubMed | Google Scholar

  11. Gressett SM, Stanford BL and Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006; 12(3): p 131-41. PubMed | Google Scholar

  12. Son HS et al. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J. 2009;50(6):p796-802. PubMed | Google Scholar